

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form, 1449A/PTO **USNP of PCT/EP02/12533** Application Number INFORMATION DISCLOSURE 8 November 2002 (08.11.2002) Filing Date STATEMENT BY APPLICANT H. EGGENWEILER et al. First Named Inventor **Group Art Unit** unassigned (use as many sheets as necessary) **Examiner Name** unassigned **MERCK-2893** Attorney Docket Number Sheet of

	•	•	U.S. P	ATENT DOCUMENTS	
Examiner Initials *	Cite No.1	U.S. Patent Document			Date of Publication of Cited Document
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY
SM	001	4,229,453		Roth, et al.	10-21-1980
SM	002	5,328,910		Rodney B. Hargreaves	07-12-1994
		•			
_		••			

	•			FOREIGI	N PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant		
		Office ³	Number ⁴	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T*
	003	EP	0005205		Troponwerke OmbH & Co.	11-14-1979 -		
	.004	<u>5</u> P	-0482804		ICI PLC	04-29-1003		
	005	DE	3145287		Troponworke CmbH & Co.	05-10-1003		
	006	wo	. 94 13070		PFIZER INC.	06-23-1094		
	007	WO	0157025		Pfizer Products Inc.	08-03-2001		
	008	wa	0130040		- Merch Patent Gmbh	04-20-2001		
	009	WO	0134601		Morek Patent Gmbh	05-17-2001		
	010	WO	0132618		Morek Patent Cmbh	05-10-2001		

Examiner Signature	/Susanna Moore/	Date Considered	05/25/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

23 JUN 2004 10/5UUU 40

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information untess it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO USNP of PCT/EP02/12533 **Application Number** INFORMATION DISCLOSURE 8 November 2002 (08.11.2002) Filing Date STATEMENT BY APPLICANT H. EGGENWEILER et al. First Named Inventor **Group Art Unit** unassigned (use as many sheets as necessary) unassigned **Examiner Name MERCK-2893** Sheet 2 **Attorney Docket Number**

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	011	K. EGER ET AL. "Selected Reactions on the o-Aminonitrile System of Substituted Pyrroles" J. HETEROCYCL. CHEM., Bd. 24, Nr. 2, 1987	
	012	C.E. MUELLER ET AL. "7. Dogga, 2-phonyladenines: Structure, Activity Relationships of Potent A1. Selective Receptor Antagonists" J. MED. CHEM., Bd. 33, Nr. 10, 1990	
	013	M_ADENOT ET AL. "Interest of cluster significance enalysis in structure affinity relationships for non- xanthine heterocyclic antagonists of adenosine" EUR. J. MED. CHEM Bd. 32, Nr. 6, 1997	
	014	A MIYASHITA ET AL "Preparation of beteroarenecarbonitriles by reaction of baleholoreerenes with postassium cyanide catalyzed by sodium p-toluenesulfinate" HETEROCYCLES, Bd. 39, Nr. 1, 1994	
· · · ·	015	G. FOLKERS, HD. HOLTJE Active site molecular modelling of xantiline oxidase inhibitors with anti-inflammatory activity" J MOLECULAR GRAPHICS, Bd. 3, Nr. 4, 1985	
	016	D. STEINI-III. BER ET AL. "New Close of 5 Lipenygenese Inhibitors: Gerrelation Between Inhibition of LTB4 Production and ChemilumInescence of Human Polymorphonuclear Granulocytes" PHARM. RESEARCH Bd. 3, Nr. 5, 1986	
	017	F. JOHANNSEN ET AL. "Reactions of Heterocyclic o Aminonitriles with Acetic Formic Anhydride" CHEMICA SCRIPTA, Bd. 26, Nr. 2, 1986	
	018	H.J. ROTH, K. EGER "Synteses von Pyrrolo"2,3 dipyrimidinon" ARCH, PHARMAZ., Bd. 808, Nr. ≠, 1975	
	019	J.W. DALY ET AL. "7 Doore 9 phenyledonines. A new class of edonesine receptor entegenists." BIOCHEM. PHARMACOL., Bd. 37, Nr. 19, 1988	
	020	A O ARDELHAMID ET AL "Reactions with beterocyclic enaminopitriles: synthesis of pyrrolo'2.3. blpyridine, pyrrolo'2,3-d!pyrimidine and pyrrole derivatives" HETEROCYCLES, Bd. 27, Nr. 8, 1988	
	021	S_KLUMPP ET AL. "Pyrrolo"2,3 dipyrimidinos as inhibiters of cAMP Phosphodiostorase" BIOOHEM. PHARMACOL., Bd. 38, Nr. 6, 1989	
	022	A. MIYASHITA ET AL. "Catalytic Action of Azolium Solta, IX. Synthesis of S. Azoyl 9H purines and Their Analogues by Nucleophilic Aroylation Catalyzed by Imidazolium or Benzimidazolium Salt" CHEM. PHARM. BULL., Bd. 46, Nr. 3, 1998	
	023	G. FOLKERG. "Rezeptoreffinitat von Xanthinoxidase Inhibitoron strukturelle Voreussetzungen". DEUTSCHE APOTHEKER ZEITUNG, Bd. 126, Nr. 41, 1986	

Examiner Signature	/Susanna Moore/	Date not Considered	05/25/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria; VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.